Q-omics provides the consensus-scored ZBTB24 profile across patient tissues and cancer cell-line models. ZBTB24 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZBTB24 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZBTB24 RNA expression shows 21,079 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where ZBTB24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB24 survival associations across molecular data types. ZBTB24 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB24 RNA expression–survival associations across cancer types. High ZBTB24 expression shows unfavorable associations in LIHC, ACC and KIRP, but favorable associations in UCS, HNSC and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZBTB24 RNA expression.
This table summarizes ZBTB24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB24 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, BLCA, STAD and LIHC. The HNSC box plot shows higher ZBTB24 RNA expression in tumor versus normal tissue (log2 FC = +0.824, t-test p < 0.001).
This table shows molecular features associated with ZBTB24 in patient tissues and cancer cell lines. In patient samples, ZBTB24 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
